Tacrolimus (FK506) and methotrexate regimens to prevent graft-versus-host disease after unrelated dog leukocyte antigen (DLA) nonidentical marrow transplantation

Bone Marrow Transplantation

Volumn 17, Issue 4, 1996, Pages 649-653

  Yu, C ^b   Storb, R ^a   Deeg, H J ^b   Graham, T C ^b   Schuening, F G ^b   Huss, R ^b   Seidel, K ^b   Fitzsimmons, W E ^b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b NONE

Author keywords

FK506; GVHD; Methotrexate; Toxicity

Indexed keywords

LEUKOCYTE ANTIGEN; METHOTREXATE; TACROLIMUS;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE MARROW TRANSPLANTATION; CONTROLLED STUDY; DOG; DRUG POTENTIATION; GASTROINTESTINAL TOXICITY; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HISTOINCOMPATIBILITY; INTRAVENOUS DRUG ADMINISTRATION; INTUSSUSCEPTION; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; WHOLE BODY RADIATION;

ANIMALS; BONE MARROW TRANSPLANTATION; DOGS; DRUG SYNERGISM; GRAFT REJECTION; GRAFT VS HOST DISEASE; HISTOCOMPATIBILITY; HISTOCOMPATIBILITY ANTIGENS; IMMUNOSUPPRESSIVE AGENTS; INTUSSUSCEPTION; METHOTREXATE; RADIATION CHIMERA; TACROLIMUS; TRANSPLANTATION CONDITIONING;

EID: 0029883643     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Storb R, Raff RF, Appelbaum FR et al. FK506 and methotrexate prevent graft-versus-host disease in dogs given 9.2 Gy total body irradiation and marrow grafts from unrelated DLA-non-identical donors. Transplantation 1993; 56: 800-807.
2. Nash RA, Etzioni R, Storb R et al. Tacrolimus (FK506) alone or in combination with methotrexate or methylprednisolone for the prevention of acute graft-versus-host disease after marrow transplantation from HLA-matched siblings: a single-center study. Blood 1995; 85: 3746-3753.
3. Ladiges WC, Deeg HJ, Raff RF, Storb R. Immunogenetic aspects of a canine breeding colony. Lab Anim Sci 1985; 35: 58-62.
4. Bull RW, Vriesendorp HM, Cech R et al. Joint Report of the Third International Workshop on Canine Immunogenetics. II. Analysis of the serological typing of cells. Transplantation 1987; 43: 154-161.
5. Deeg HJ, Raff RF, Grosse-Wilde H et al. Joint Report of the Third International Workshop on Canine Immunogenetics: I. Analysis of homozygous typing cells (HTCs). Transplantation 1986; 41: 111-117.
6. Burnett RC, DeRose SA, Storb R. A simple restriction fragment length polymorphism assay for MHC class U gene testing of dog families. Transplantation 1994; 57: 280-282.
7. Ladiges WC, Storb R, Graham T, Thomas ED. Experimental techniques used to study the immune system of dogs and other large animals. In: Gay WI, Heavener JE (eds). Methods of Animal Experimentation. Vol 7. Part C. Academic Press: New York, 1989, pp 103-133.
8. Storb R, Deeg HJ. Failure of allogeneic canine marrow grafts after total body irradiation: allogeneic 'resistance' vs trans-fusion induced sensitization. Transplantation 1986; 42: 571-580.
9. n polymorphisms to determine the origin of blood cells after allogeneic canine marrow grafting. Transplantation 1994: 58: 701-706.
10. Storb R, Deeg HJ, Raff R et al. Prevention of graft-versus-host disease: studies in a canine model. Ann NY Acad Sci (in press).
11. Storb R, Thomas ED. Graft-versus-host disease in dog and man: the Seattle experience. In: Möller G (ed). Immunological Reviews No. 88. Munksgaard: Copenhagen, 1985, pp 215-238.
12. Storb R, Thomas ED. The scientific foundation of marrow transplantation based on animal studies. In: Forman SJ, Blume KG, Thomas ED (eds). Bone Marrow Transplantation. Blackwell Scientific: Boston, MA, 1994, pp3-11.
13. Deeg HJ, Storb R, Weiden PL et al. Cyclosporine A and methotrexate in canine marrow transplantation: engraftment, graft-versus-host disease, and induction of tolerance. Transplantation 1982; 34: 30-35.
14. Deeg HJ, Storb R, Appelbaum FR et al. Combined immuno-suppression with cyclosporine and methotrexate in dogs given bone marrow grafts from DLA-haploidentical littermates. Transplantation 1984; 37: 62-65.
15. Storb R, Deeg HJ, Farewell V et al. Marrow transplantation for severe aplastic anemia: methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease. Blood 1986; 68: 119-125.
16. Storb R, Deeg HJ, Whitehead J et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft-versus-host disease after marrow transplantation for leukemia. New Engl J Med 1986; 314: 729-735.
17. Appelbaum FR, Raff RF, Storb R et al. Use of trimetrexate for the prevention of graft-versus-host disease. Bone Marrow Transplantation 1989; 4: 421-424.
18. Doney KC, Storb R, Beach K et al. A toxicity study of trimetrexate used in combination with cyclosporine as acute graft-versus-host disease prophylaxis in HLA-mismatched, related donor bone marrow transplants. Transplantation 1995; 60: 55-58.